← brief for 2026-08-14 · Slowing decline

Glucagon-like peptide 1 receptor agonists in cardiovascular-kidney-metabolic syndrome: a review

Paper No results yet Peer reviewed

Key takeaways

This review looks at GLP-1 drugs, like semaglutide, in people who have heart, kidney, and metabolic problems at the same time. The authors gathered what earlier studies found about whether these drugs protect the kidneys and heart. It is a summary of past work, not a new trial, so there are no fresh results here.

Who did this work

Jing Zhou (Second Affiliated Hospital of Xi'an Jiaotong University) · Nenghan Zhang (Second Affiliated Hospital of Xi'an Jiaotong University) · Jiajun Li (Second Affiliated Hospital of Xi'an Jiaotong University) · Xiangqi Qin (Second Affiliated Hospital of Xi'an Jiaotong University) · Lingqi Kong (Second Affiliated Hospital of Xi'an Jiaotong University) · Liang Bai (Xi'an Jiaotong University) · Tuo Han (Second Affiliated Hospital of Xi'an Jiaotong University)

Source

Paper · OpenAlex, CKD works · 2026-08-13
https://doi.org/10.37349/eemd.2026.101481